Sub-Study within Project ANNOTeM (Acute Neurological care in North-East-Germany with Tele-medical Support) Effects of telemedically supported differential diagnosis and therapy of epileptic seizures – a prospective, multi-center, open-label, controlled, cluster-randomized, parallel-group study

Organizational Data

DRKS-ID:
DRKS00013068
Recruitment Status:
Recruiting complete, study complete
Date of registration in DRKS:
2017-09-26
Last update in DRKS:
2023-01-09
Registration type:
Prospective

Acronym/abbreviation of the study

ANNOTeM-EPI

URL of the study

http://www.annotem.de

Brief summary in lay language

Patients admitted to the clinics of the ANNOTeM network with epileptic seizures or unclear disorders of consciousness receive telemedical consultation from a specialist in the field of epilepsy. In addition, data on quality of life and understanding of disease are collected. Six months later, the study participants are contacted again and questions are asked for example about the course of the disease, possible future hospital stays and quality of life. Website www.annotem.de is currently under construction. Further informationen availabel at: https://innovationsfonds.g-ba.de/projekte/neue-versorgungsformen/annotem-akut-neurologische-versorgung-in-nord-ost-deutschland-mit-telemedizinischer-unterstuetzung.76 as well as at https://www.charite.de/service/pressemitteilung/artikel/detail/telemedizinische_vernetzung_verbessert_versorgung_neurologischer_notfaelle/

Brief summary in scientific language

Participating study centers will be cluster-randomized in clinics A with tele-epilepsy consultation and B without tele-epilepsy consultation and will change their assignment after the half of the project time. Primary analysis population is the Intention-To-Treat population which includes all enrolled participants. If the primary endpoint is missing, patient’s outcome will be treated as censored for the time of the last contact. Time until till re-hospitalization within 6 months after study inclusion due to an epileptic seizure or loss of consciousness of unknown origin will be analyzed by a cox-regression model. Sensitivity analyses will be carried out as well to adjust for potential confounders (for example gender). If within the time of 6 month recurrent hospitalizations will be observed, additionally analysis, which deal with recurrent events, will be conducted. For example a regression model by Wei-Lin-Weissfeld [1][2], fits the time until event number k depended the time till the preceding events, or a model by Prentice-Williams-Peterson[3], which fits a model for the time until event number k depended the counts of preceding events. Secondary endpoints will be analyzed in an exploratory manner, using appropriate parametric and non-parametric statistical methods, depending on their scale and distribution. Ninety-five percent confidence intervals will be calculated. Secondary analysis will be carried out for the per-protocol-population, which means missing values will not be imputed.

Health condition or problem studied

ICD10:
G40 - Epilepsy
ICD10:
G41 - Status epilepticus
ICD10:
R40 - Somnolence, stupor and coma
Healthy volunteers:
No Entry

Interventions, Observational Groups

Arm 1:
A with tele-epilepsy consultation: Within 48 hours after an acute hospital admission due to an epileptic seizure or unconsciousness of unknown origin, the patients are advised individually by epileptologists for about 1-2 hours. This is done via a telemedical system with voice, data and video conference communication. If possible, a third party medical history is taken in addition to the patient's own medical history. The attending physician then draws up a separate summary for the patient and the attending physician in the cooperating clinic. Baseline data (before consultation) and follow-up data (6 months after the start of the study) will be recorded.
Arm 2:
"B" without tele-epilepsy consultation and standard care: Only Baseline and Follow-Up (6 months after study inclusion) data will be recorded

Endpoints

Primary outcome:
time till re-hospitalization within 6 months after study inclusion due to an epileptic seizure or loss of consciousness of unknown origin measured in days
Secondary outcome:
Frequency of seizure (predefined subgroups: Newly occurring epilepsy and pre-existing epilepsy, as well as all patients with loss of consciousness with a suspected epilept. seizure) within 6 months after the index visit; Frequency of hospital admissions with similar symptoms within 6 months after the index visit; AU days (days of incapacity for work) within 6 months after the index visit; Change in quality of life (PROMIS-29, QOLIE 31, PESOS-2010E) between the index visit and 6 months after the index visit;

Study Design

Purpose:
Prevention
Allocation:
Randomized controlled study
Control:
  • Control group receives no treatment
Phase:
N/A
Study type:
Interventional
Mechanism of allocation concealment:
No Entry
Blinding:
No
Assignment:
Parallel
Sequence generation:
No Entry
Who is blinded:
No Entry

Recruitment

Recruitment Status:
Recruiting complete, study complete
Reason if recruiting stopped or withdrawn:
No Entry

Recruitment Locations

Recruitment countries:
  • Germany
Number of study centers:
Multicenter study
Recruitment location(s):
  • Medical center Evangelisches Krankenhaus Ludwigsfelde-Teltow Ludwigsfelde
  • Medical center KMG Klinikum Kyritz Kyritz
  • Medical center Sana Krankenhaus Rügen Bergen
  • Medical center Ameos Klinikum Ueckermünde Ueckermünde
  • Medical center Krankenhaus Märkisch-Oderland Strausberg
  • Medical center Sana Krankenhaus Templin Templin
  • Medical center DRK Krankenhaus Luckenwalde Luckenwalde
  • Medical center Havelland-Kliniken Nauen
  • Medical center Havelland-Kliniken Rathenow
  • Medical center Altmark-Klinikum Gardelegen

Recruitment period and number of participants

Planned study start date:
2017-10-01
Actual study start date:
2017-11-29
Planned study completion date:
No Entry
Actual Study Completion Date:
2020-02-22
Target Sample Size:
800
Final Sample Size:
134

Inclusion Criteria

Sex:
All
Minimum Age:
18 Years
Maximum Age:
no maximum age
Additional Inclusion Criteria:
Patients in regional care clinics with neurological emergency syndromes such as disturbances of consciousness or epileptic seizures with or without diagnosed epilepsy.

Exclusion Criteria

non-acute syndromes (>24h), non neurological syndromes

Addresses

Primary Sponsor

Address:
Charité Universitätsmedizin Berlin
Charitéplatz 1
10117 Berlin
Germany
Telephone:
No Entry
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry
Investigator Sponsored/Initiated Trial (IST/IIT):
Yes

Contact for Scientific Queries

Address:
Charité Universitätsmedizin Berlin
Doktor Joachim Weber
Hindenburgdamm 30
12203 Berlin
Germany
Telephone:
+49 30450543524
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Contact for Public Queries

Address:
Charité Universitätsmedizin Berlin
Doktor Joachim Weber
Hindenburgdamm 30
12203 Berlin
Germany
Telephone:
+49 30450543524
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Principal Investigator

Address:
Charité Universitätsmedizin Berlin
Doktor Joachim Weber
Hindenburgdamm 30
12203 Berlin
Germany
Telephone:
+49 30450543524
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Sources of Monetary or Material Support

Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)

Address:
Gemeinsamer Bundesausschuss, Innovationsausschuss
Wegelystrasse 8
10623 Berlin
Germany
Telephone:
+49 22838211120
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Ethics Committee

Address Ethics Committee

Address:
Ethikkommission der Charité – Universitätsmedizin Berlin
Charitéplatz 1
10117 Berlin
Germany
Telephone:
(+49)30-450517222
Fax:
(+49)30-450517952
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Vote of leading Ethics Committee

Vote of leading Ethics Committee
Date of ethics committee application:
2017-06-07
Ethics committee number:
EA4/114/17
Vote of the Ethics Committee:
Approved
Date of the vote:
2017-07-03

Further identification numbers

Other primary registry ID:
No Entry
EudraCT Number:
No Entry
UTN (Universal Trial Number):
U1111-1202-4324
EUDAMED Number:
No Entry

IPD - Individual Participant Data

Do you plan to make participant-related data (IPD) available to other researchers in an anonymized form?:
No
IPD Sharing Plan:
No Entry

Study protocol and other study documents

Study protocols:
Weber JE, Angermaier A, Bollweg K, et al. Acute neurological care in north-east Germany with telemedicine support (ANNOTeM): protocol of a multi-center, controlled, open-label, two-arm intervention study. BMC health services research. 2020;20(1):755.
Study abstract:
No Entry
Other study documents:
No Entry
Background literature:
No Entry
Related DRKS studies:
No Entry

Publication of study results

Planned publication:
No Entry
Publikationen/Studienergebnisse:
Hebun Erdur MD, Joachim E. Weber MD, Anselm Angermaier MD et al. A Managed Care System with Telemedicine Support for Neurological Emergencies, Annals of Neurology, 2022, ana.26556
Date of first publication of study results:
2022-11-18
DRKS entry published for the first time with results:
No Entry

Basic reporting

Basic Reporting / Results tables:
No Entry
Brief summary of results:
No Entry